Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8495466 | 1.00 | TSHR (0.43) | TSHRALDH1A1TET2GRM2GRM3 | |
| SCHEMBL3248330 | 1.00 | TSHR (0.43) | TSHRALDH1A1TET2GRM2GRM3 | |
| SCHEMBL5704287 | 0.82 | TET2 (0.46) | TSHRALDH1A1TET2HMGCRCHRM1 | |
| SCHEMBL31306975 | 0.81 | TET2 (0.38) | TSHRALDH1A1TET2HMGCRCHRM1 | |
| SCHEMBL25564418 | 0.80 | FDPS (0.45) | TSHRALDH1A1TET2GRM2GRM3 | |
| SCHEMBL28052626 | 0.80 | TET2 (0.45) | TSHRALDH1A1TET2HMGCRCHRM1 | |
| SCHEMBL28215292 | 0.80 | TET2 (0.40) | TSHRALDH1A1TET2HMGCRCHRM1 | |
| SCHEMBL27931384 | 0.80 | TET2 (0.45) | TSHRALDH1A1TET2HMGCRCHRM1 | |
| SCHEMBL1782336 | 0.79 | ALDH1A1 (0.38) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| Ammonia Solution, Strong SCHEMBL27462515 | 0.78 | TET2 (0.43) | TSHRALDH1A1TET2HMGCRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752852-B2 | Fuel additive | INNOTECH LTD. (RU) | 2020-08-25 | — | — | US | claimed |
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | claimed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | claimed |
| EP-2788326-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2014-10-15 | — | — | EP | claimed |
| CN-104039767-A | N- (pyridin-4-yl) amides and N- (pyrimidin-4-yl) amides and their pharmaceutical and cosmetic use | GALDERMA RES & DEV | 2014-09-10 | — | — | CN | claimed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | claimed |
| WO-2013064681-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-10 | — | — | WO | claimed |
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-9732044-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-15 | — | — | US | disclosed |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2788326-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2014-10-15 | — | — | EP | disclosed |
| CN-104039767-A | N- (pyridin-4-yl) amides and N- (pyrimidin-4-yl) amides and their pharmaceutical and cosmetic use | GALDERMA RES & DEV | 2014-09-10 | — | — | CN | disclosed |
| EP-1861382-B1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-7834036-B2 | Fused-aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME CORP (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| EP-1861382-A1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006096564-A1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2006-09-14 | — | — | WO | disclosed |
| US-5457085-A | Herbicides | SANDOZ LTD. (CH) | 1995-10-10 | — | — | US | disclosed |
| EP-0531700-A2 | Pure diastereomere intermediates and their use in the preparation of (R)- or (S)-ketoprofen | BAYER AG (DE) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | NR5A1, AR, CYP19A1 | TSHR 358/4885ALDH1A1 1847/4885TET2 3507/4885 |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | PPARG, PPARA, FABP4 | TSHR 631/4885ALDH1A1 2353/4885TET2 4122/4885 |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | AR, NR5A1, PPARA | TSHR 237/4885ALDH1A1 2442/4885TET2 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.